Key highlights from 2023
Key highlights from 2023
January
Mexico: Darrow, the expert brand
for Latin-American skin types, was launched. It is already number two on the Brazilian dermo- cosmetics market.
February
Toulouse Oncopole Innovation Center:
new laboratories were opened, specializing in targeted therapies for oncology.
March
Spor’Team Pierre Fabre was launched:
11 young athletes from the Occitania region received support from Pierre Fabre as they trained to compete in major international competitions.
April
Partnership with Scorpion Therapeutics
to develop two targeted therapies for the treatment of lung cancer.
Même Cosmetics was acquired.
The No. 1 brand for dermo-cosmetic care products to alleviate the adverse effects of cancer drugs.
June
AFNOR SPEC 2215 was published,
establishing guidelines for informing consumers about the social and environmental impact of cosmetics and healthcare products. This methodology was compiled by the Green Impact Index Consortium.
In Shanghai,
a dermo-cosmetics innovation center was inaugurated, devoted to caring for Asian skin types.
July
Marking the 10-year anniversary, of the passing of Mr. Pierre Fabre,
a ceremony was held to inaugurate the new headquarters of the Pierre Fabre Foundation.
September
We acquired the biotech firm Vertical Bio
and its drug candidate VERT-002 for the treatment of lung cancer.
We acquired a stake in MiYé,
a French startup specialized in care products and dietary supplements for female hormonal balance and well-being.
October
11,000 employees attended conferences and workshops held during “Skill Week” focused on data and AI.
Pierre Fabre Laboratories was ranked one of the “World’s Best Employers”
by Forbes magazine, for the 3rd year running.
November
United-States: we obtained licensing rights for EBVALLO® ,
an immunotherapy indicated for the treatment of a rare lymphoproliferative disorder.
December
€1BN
Eau Thermale Avène joined the prestigious club of cosmetic brands with their net sales.
Prix Galien award
EBVALLO® received this rare distinction in France in the “Advanced Therapy Medicinal Product” category.